Literature DB >> 32167090

HIV in Canada-Surveillance Report, 2018.

N Haddad1, A Robert1, A Weeks1, N Popovic1, W Siu1, C Archibald1.   

Abstract

BACKGROUND: Human immunodeficiency virus (HIV) is a global public health issue, with an estimated 36.9 million people living with HIV in 2017. HIV has been reportable in Canada since 1985 and the Public Health Agency of Canada (PHAC) continues to monitor trends in new HIV diagnoses.
OBJECTIVE: The objective of this surveillance report is to provide an overview of the epidemiology of all reported diagnoses of HIV in Canada since 1985 with a focus on 2018 overall, and by geographic location, age group, sex, and exposure category.
METHODS: PHAC monitors HIV through the national HIV/AIDS Surveillance System, a passive, case-based system that collates nonnominal data that is voluntarily submitted by all Canadian provinces and territories. Descriptive epidemiological analyses were conducted on national data and those relating to specific populations provided by Immigration, Refugees and Citizenship Canada and the Canadian Perinatal HIV Surveillance Program.
RESULTS: In 2018, a total of 2,561 HIV diagnoses were reported in Canada, an increase of 8.2% compared with 2017. The national diagnosis rate increased to 6.9 per 100,000 population in 2018 from 6.5 per 100,000 population in 2017. Saskatchewan reported the highest provincial diagnosis rate at 14.9 per 100,000 population. The 30-39 year age group continued to have the highest HIV diagnosis rate at 15.4 per 100,000 population. Overall, the diagnosis rate for males continued to be higher than that of females (9.8 versus 4.0 per 100,000 population, respectively); however, females experienced a larger increase in reported cases and diagnosis rate. The gay, bisexual and other men who have sex with men (gbMSM) exposure category continued to represent the highest proportion of all reported adult cases (41.4%), though the proportion has decreased over time. Five perinatal HIV transmissions were documented, three were related to the mother not receiving perinatal antiretroviral therapy prophylaxis.
CONCLUSION: The number and rate of reported HIV cases in Canada increased in 2018, gbMSM continued to account for the largest exposure category and the number and rate of reported HIV cases among women increased. PHAC will continue to work with its national partners to refine the collection, analysis and publication of national data to better understand the burden of HIV in Canada.

Entities:  

Keywords:  Canada; HIV; bisexual and other men who have sex with men; gay; heterosexual contact; people who inject drugs; perinatal HIV; surveillance

Year:  2019        PMID: 32167090      PMCID: PMC7043211          DOI: 10.14745/ccdr.v45i12a01

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN: 1188-4169


  6 in total

1.  Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs.

Authors:  Gary Marks; Nicole Crepaz; J Walton Senterfitt; Robert S Janssen
Journal:  J Acquir Immune Defic Syndr       Date:  2005-08-01       Impact factor: 3.731

2.  Prevention of HIV-1 infection with early antiretroviral therapy.

Authors:  Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming
Journal:  N Engl J Med       Date:  2011-07-18       Impact factor: 91.245

3.  Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995-2015.

Authors: 
Journal:  Lancet       Date:  2018-04-17       Impact factor: 79.321

4.  HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care.

Authors:  Lisa R Metsch; Margaret Pereyra; Shari Messinger; Carlos Del Rio; Steffanie A Strathdee; Pamela Anderson-Mahoney; Ellen Rudy; Gary Marks; Lytt Gardner
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

5.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.

Authors: 
Journal:  Lancet       Date:  2008-07-26       Impact factor: 79.321

6.  HIV in Canada-Surveillance Report, 2017.

Authors:  N Haddad; J S Li; S Totten; M McGuire
Journal:  Can Commun Dis Rep       Date:  2018-12-06
  6 in total
  22 in total

1.  HIV in Canada-surveillance report, 2019.

Authors:  Nisrine Haddad; Ashley Weeks; Anita Robert; Stephanie Totten
Journal:  Can Commun Dis Rep       Date:  2021-01-29

2.  Leaving no one behind? An equity analysis of the HIV care cascade among a cohort of people living with HIV in Manitoba, Canada.

Authors:  Leigh M McClarty; James F Blanchard; Marissa L Becker
Journal:  BMC Public Health       Date:  2021-02-04       Impact factor: 3.295

3.  Combination HIV Prevention Strategies Among Montreal Gay, Bisexual, and Other Men Who Have Sex with Men in the PrEP Era: A Latent Class Analysis.

Authors:  Carla M Doyle; Mathieu Maheu-Giroux; Gilles Lambert; Sharmistha Mishra; Herak Apelian; Marc Messier-Peet; Joanne Otis; Daniel Grace; Trevor A Hart; David M Moore; Nathan J Lachowsky; Joseph Cox
Journal:  AIDS Behav       Date:  2021-01

4.  Understanding the impact of a residential housing programme for people living with HIV/AIDS: a realist evaluation protocol.

Authors:  Shaneice Fletcher-Hildebrand; Hubert Alimezelli; Tracey Carr; Karen Lawson; Anum Ali; Gary Groot
Journal:  BMJ Open       Date:  2021-04-05       Impact factor: 2.692

5.  Decentralizing PrEP delivery: Implementation and dissemination strategies to increase PrEP uptake among MSM in Toronto, Canada.

Authors:  Maxime Charest; Malika Sharma; Allison Chris; Alexandre Schnubb; David C Knox; James Wilton; Rita Shahin; Arlene Chan; Sharmistha Mishra; Daniel Grace; Ahmed M Bayoumi; John Maxwell; Isaac I Bogoch; Darrell H S Tan
Journal:  PLoS One       Date:  2021-03-18       Impact factor: 3.240

6.  Hospital admissions and mortality due to complications of injection drug use in two hospitals in Regina, Canada: retrospective chart review.

Authors:  Polina Tsybina; Sandy Kassir; Megan Clark; Stuart Skinner
Journal:  Harm Reduct J       Date:  2021-04-21

7.  The Role of Phylogenetics in Unravelling Patterns of HIV Transmission towards Epidemic Control: The Quebec Experience (2002-2020).

Authors:  Bluma G Brenner; Ruxandra-Ilinca Ibanescu; Nathan Osman; Ernesto Cuadra-Foy; Maureen Oliveira; Antoine Chaillon; David Stephens; Isabelle Hardy; Jean-Pierre Routy; Réjean Thomas; Jean-Guy Baril; Roger Leblanc; Cecile Tremblay; Michel Roger
Journal:  Viruses       Date:  2021-08-19       Impact factor: 5.048

8.  Trends in HIV pre-exposure prophylaxis use in eight Canadian provinces, 2014-2018.

Authors:  Nashira Popovic; Qiuying Yang; Chris Archibald
Journal:  Can Commun Dis Rep       Date:  2021-06-09

Review 9.  Social, Clinical, and Behavioral Determinants of HIV Infection and HIV Testing among Black Men in Toronto, Ontario: A Classification and Regression Tree Analysis.

Authors:  Pascal Djiadeu; Martez D R Smith; Sameer Kushwaha; Apondi J Odhiambo; David Absalom; Winston Husbands; Wangari Tharao; Rotrease Regan; Ting Sa; Nanhua Zhang; Rupert Kaul; LaRon E Nelson
Journal:  J Int Assoc Provid AIDS Care       Date:  2020 Jan-Dec

10.  Longitudinal Event-Level Sexual Risk and Substance Use among Gay, Bisexual, and Other Men Who Have Sex with Men.

Authors:  Jordan M Sang; Zishan Cui; Paul Sereda; Heather L Armstrong; Gbolahan Olarewaju; Allan Lal; Kiffer G Card; Eric A Roth; Robert S Hogg; David M Moore; Nathan J Lachowsky
Journal:  Int J Environ Res Public Health       Date:  2021-03-19       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.